Astellas Pharma Inc (ALPMF) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much for joining our FY2024 Financial Results Announcement meeting by Astellas Pharma Inc. out of a very busy schedule today. I'm delighted to serve as a moderator. I'm Ikeda, Chief Communications and IR Officer. Thank you for your time. Today, after presentation, we will move on to Q&A session. Presentation will be made based on the material posted on our website under the IR meeting section. We have simultaneous translation between Japanese and English, including Kyonei. We cannot guarantee the accuracy of the translation. Thank you for your understanding. You can choose the language from the menu on the Zoom webinar screen. If you select the original language, you can listen to the original sound without going through the translation. Disclaimer for today. This material or presentation by representatives for the company and their answers and statement in the Q&A session includes forward-looking statements based on assumptions and beliefs in light of information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors. They contain information on pharmaceuticals, including compounds and development, but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations, promote unapproved use in any fashion, or provide medical advice of any kind. Let me introduce the participants. Naoki Okamura, Representative Director, President, and CEO. Chief Research and Development Officer, Tadaaki Taniguchi. Chief Commercial and Medical Affairs Officer, Klaus Zieder. And Chief Financial Officer, Atsushi Kitamura. We have four executives. We would like to have a presentation. Okamur...